Our Team

Ashley R. Robinson has over 20 years of experience in institutional equity finance, with a focus on the healthcare sector. He began his Wall Street career at Lehman Brothers Holdings, Inc., where he spent time in both the New York and Boston offices after successfully completing the firm’s extensive capital markets training program. Mr. Robinson then spent 15 years at Leerink Partners (formerly Leerink Swann; now SVB Leerink), where he was a Managing Director and Sr. Partner. At Leerink, Mr. Robinson helped establish and build the institutional franchise, and was responsible for the firm’s largest client relationships. During Leerink’s rise to prominence as one of the leading healthcare investment banks, Mr. Robinson developed deep relationships with the leading US healthcare investors. He served as “Deal Captain” on the majority of Leerink’s capital markets transactions, and was the primary liaison between sales, trading and equity capital markets. Prior to joining LifeSci, Mr. Robinson was the Healthcare Product Specialist and Sector Head at Guggenheim Securities, LLC, where he was responsible for building a research franchise in that sector. Mr. Robinson earned a Bachelor of Arts degree from Hobart College where he was a three-sport athlete and double-majored in Economics and Russian Area Studies.

Bob Yedid has 30 years of healthcare experience as a buy-side analyst, portfolio manager, growth equity investor and investment banker. He has extensive experience with healthcare companies, especially in the medtech/diagnostic, specialty pharma and biotech sectors. Bob focuses on providing CEOs and CFOs with strategic advice on key investor issues to enhance stock valuation through effective and compelling messaging and clear, consistent communications with institutional investors. Bob’s experience and perspective as an investor in public and private healthcare companies informs his strategic investor relations work for companies with market capitalizations from $100 million to over $5 billion. He has worked with biopharma, medtech and diagnostic companies in providing ongoing investor relations advice as well as working on IPOs, follow-on offerings and equity-linked securities. In addition, Bob has advised companies in M&A transactions, dual track processes, and C-suite executive transitions. Before working with healthcare companies on investor relations starting in late 2011, Bob was a Portfolio Manager and Senior Research Analyst at Principled Capital, a fund with $1.5 billion of AUM, for 10 years with responsibility for all health care investing. Prior to Principled, he was a Vice President at Warburg Pincus, one of the world’s largest private equity and venture capital firms, investing in health care. Bob was a member of the Board of Directors of The Medicines Company (MDCO, acquired by Novartis) and Eurand International. He also spent 15 years in investment banking, including serving as Managing Director in Healthcare Finance Group at Bear Stearns & Co. (now JP Morgan), having worked on capital markets and M&A transactions of over $5 billion. In October 2019, Bob was appointed as a member of the Board of Directors of Vaxart, a publicly traded vaccines company, and is a Board member of Enalare Therapeutics (private). Bob earned a BA in Economics from Yale University and an MBA from Stanford University Graduate School of Business.

Brian Ritchie has over 20 years of healthcare investor relations and communications experience. He focuses on developing, implementing
and overseeing investor relations programs for leading medical technology, biotechnology, specialty pharmaceutical, and
healthcare services companies. Brian has also worked on a number of financial transactions, including IPOs, follow-on
offerings, venture rounds, and M&A agreements. Prior to joining LifeSci, he spent over eight years at FTI Consulting as a
Senior Director within the Strategic Communications segment’s Capital Markets Practice and healthcare & life sciences
sector. Previously, Brian spent nearly six years at Noonan/Russo Communications, where, in increasingly senior positions, he
focused on investor relations for a large variety of life sciences and healthcare companies. He holds a B.S. in communication
arts from St. John’s University, where he graduated Cum Laude.

Bruce Mackle brings nearly 25 years of healthcare-dedicated experience in the financial industry on the sell-side, on the buy-side and as an investor relations advisor. Over the course of his career, Bruce primarily served as a healthcare trading desk analyst and a healthcare sector sales specialist at firms including Wells Fargo, UBS, HSBC, and most recently, JMP. Prior to JMP, he worked at Bertner Advisors, a healthcare-focused investor relations advisory firm, where he managed a client portfolio of both public and pre-IPO companies. His buy-side experience includes positions at two healthcare-dedicated funds, Tokum Capital and Steeple Capital. Bruce began his Wall Street career as a healthcare equity research analyst at Gruntal & Co. and UBS. He earned an M.B.A. in Finance and Economics from New York University’s Stern School of Business and a B.A. from Cornell University.

Chuck Padala brings over 25 years of Institutional Equity Sales, Trading and ECM experience at several large investment banks, including Citigroup, Lehman Brothers and SunTrust, where he spent 20 years, and supervised the firm’s NY Sales & Trading desks. Chuck later joined Brean Capital where he ran the firm’s Equities division and was Head of ECM. Prior to joining LifeSci Advisors, Chuck also served as President of the Securities Traders Association’s NY affiliate and
served two consecutive terms on STA’s national Board of Governors. STA is the largest organization representing professional traders and was formed as a grass roots response to the founding of the SEC in 1934, in order to give market participants a voice in Washington DC. Chuck graduated with honors from New York University.

Chris Calabrese has over 20+ years in institutional equity sales, with a focus in Healthcare. Chris is a managing director at LifeSci Advisors in a relationship manager role. Joining most recently from Ladenburg Thalmann where he was the head of Healthcare Sales. Chris spent 10 years at Ladenburg where he was a managing director in sales coverage for a range of buyside healthcare accounts from all around the country. Chris started his career in Capital Markets Institutional Sales back in 2000. Prior to Ladenburg he was in a similar role as an MD in healthcare sales at WJB Capital for over 5 years. He was also head of business development and instrumental in the creation of their corporate access platform. Chris helped oversee all operations and roadshow calendar. Chris graduated from WestChester University in 1992 with a Bachelor of Arts Degree in Communications. He holds his series 7 & 63 licenses.

Prior to joining LifeSci Advisors as a Managing Director and Relationship Manager in 2019, Corey Davis had 22 years of experience as a sell-side equity research analyst covering a diverse array of biotech and specialty pharmaceutical companies. He was previously a Senior Analyst and Managing Director at Seaport Global Securities, Canaccord Genuity, Jefferies, HC Wainwright, Natixis Bleichroeder, and J.P. Morgan (and its predecessor Hambrecht & Quist). His formal coverage universe has included well over 200 companies throughout the course of his career. As a long-term sellside analyst at several premier investment banks, he has covered and advised countless executives at both public and private on a wide variety of matters including corporate messaging, investor targeting, capital raising, earnings targets, clinical trial design and interpretation, strategic directions, etc. He has extensive experience in developing proprietary predictive financial models, exhaustive writing and presentation skills, and refined abilities to deliver convincing opinions and recommendations to the sophisticated healthcare institutional investor audience. He is valued for his forward thinking and two+ decades of interactions with healthcare specialists at all of the leading buyside and venture capital firms. His network of contacts among biopharma corporate executives, healthcare investors, and industry thought leaders spans almost every therapeutic area of pharmaceutical development. Sine 2019 at LifeSci Advisors, he is focused exclusively on advising both public and private biotech clients on all aspects of capital markets to help them optimize relationships and communications with the investor community in order to secure the necessary funding for clinical development and execute on corporate strategy. He has won numerous awards including multiple Institutional Investor rankings, and The Wall Street Journal’s “Best on the Street”. He graduated magna cum laude with High Honors in biology from Middlebury College in 1991 and received his Ph.D. in molecular biology from Princeton University in 1997.

Dan Ferry joins LifeSci Advisors from Guggenheim Securities, where he specialized in connecting healthcare companies with buy-side investors, venture capitalists, KOLs, sell-side analysts, and the investment bank. Mr. Ferry spent nearly 4 years at Guggenheim Securities putting together numerous non-deal roadshows, collecting feedback from investors, and helping shape investor outreach strategies. Prior to Guggenheim, Mr. Ferry worked at Lazard Capital Markets where he participated in many successful healthcare company financings. Over the course of his career, Mr. Ferry has developed long-standing relationships with the healthcare investment community. Mr. Ferry received a BS in Finance from the University of Southern California. He currently resides with his wife and three children in the Boston area.

Guillaume has more than 15 years’ experience in life sciences and finance. He worked for 10 years as a sell-side biotech analyst at Canaccord and UBS in London and Zurich before becoming an investor relations spokesperson for Sanofi and CFO of Hartis Pharma. Guillaume has a Doctorate in Pharmacy from the Université Paris Descartes and a Masters in Finance from the London Business School.

Irina Koffler has been working as a relationship manager and in corporate communications with LifeSci advisors since 2019. She has 13 years of sell-side experience covering specialty pharmaceutical, small cap biopharma, and generic stocks, with a focus on dermatology, gastroenterology, CNS and anti-infective stocks. She has previously worked at UBS and was Managing Director of Specialty Pharmaceuticals at both Cantor Fitzgerald, and Mizuho Securities. Prior to her Wall Street career, Irina spent 10 years in industry, working across both clinical research and marketing roles at companies including Forest Laboratories, and contract research organizations such as Quintiles. Irina has a B.A. in Biological Sciences from Cornell University, and M.S. in Epidemiology and Preventive Medicine from University of Maryland, and an MBA from the Leonard N. Stern School of Business at New York University.

Jeremy brings more than 20 years of experience in healthcare, both as a sell-side analyst and as an investor relations advisor. Jeremy covered both medical devices and healthcare services as an analyst at such firms as Bank of America, Oppenheimer, and Cantor Fitzgerald. As Vice President of Investor Relations at Nyoah, a dual-listed medtech company, and during a previous stint as Relationship Manager at LifeSci Advisors, he has built extensive experience developing and executing investor relations strategies for pre-IPO and publicly traded healthcare companies and counseling senior executives on messaging to Wall Street, including corporate access plans, guidance philosophy, capital markets strategy. Jeremy earned an MBA in Finance from the Leonard N. Stern School of Business at New York University, a Diploma in Economics from the London School of Economics, and a BA in Economics and Political Science from the University of Chicago.

Joyce Allaire has more than 25 years of healthcare IR and capital markets experience. She has been at LifeSci Advisors since 2013 and has been instrumental in building the business and brand, including leading the creation of the LifeSci KOL event offering. Today she operates as Managing Director and Senior Relationship Manager, working with premiere healthcare clients on all aspects of investor relations, business strategies and capital markets initiatives. She brings both a high level of industry knowledge, and also a broad reach to buy and sell-side constituencies. Joyce began her career at Hambrecht & Quist in Boston and post-merger, worked at JP Morgan in New York servicing healthcare focused institutional investors. She spent seven years at Leerink Swann & Co. as a Senior Healthcare Sales Specialist where she was responsible for research sales and capital markets efforts. Joyce received an MBA from Bentley College and graduated from Assumption College with a Bachelor of Arts in Economics and Finance.

Kevin Gardner brings over 22 years of experience in Institutional Equity Sales covering numerous research verticals in the U.S. and Europe, with a particular focus on healthcare. Gardner joins the LifeSci team after spending 10 years as Managing Director at Ladenburg Thalmann & Co., for whom he opened and successfully managed a Boston office. Kevin was instrumental in building up the Ladenburg healthcare franchise, having been closely involved in many of Ladenburg’s flagship banking transactions. Gardner started his career at Credit Lyonnais Securities (USA) where he focused on U.S. and European securities across multiple sectors, with enhanced emphasis on healthcare. Gardner then spent 10 years as Managing Director at Natexis Bleichroeder, opening up and managing their Boston office. While there, Kevin worked with some of the top healthcare analysts on Wall Street in both the U.S. and Europe, and was the driving force behind substantial growth in the firm’s revenues and exposure within the institutional investor community. Over these years, Gardner has developed strong relationships with some of the top healthcare investors in the world. Kevin has a BA in Economics from Boston College.

Mike Moyer spent 18 years on Wall Street in institutional sales at Leerink, Summer Street, and most recently at Stifel as a healthcare sector sales specialist. Prior to joining LifeSci in 2019, Mike was VP of Portfolio Strategy at Ziopharm. Mike began his career as a pharmaceutical sales representative at Dura Pharmaceuticals, and has a BA from the University of Pennsylvania.

PJ Kelleher is a Director in LifeSci’s Boston office. Since joining the firm in 2018, he has focused exclusively on advising both public and private clients on all aspects of the capital markets to help them optimize relationships and communications with the investment community. During his time at the firm, he has worked with both biopharma and medtech companies across the development stage in providing strategic investor relations support as well as advising on IPOs, follow-on offerings and equity-linked securities. Prior to joining LifeSci, he worked in investor relations at an asset management firm in Boston. PJ received his BA in Economics and Finance from Connecticut College

Sandya has over 10 years of experience in the pharmaceutical and biotech industries, working for Novartis, Merck KGaA/ EMD Serono and Debiopharm. She has built expertise in business development, driving identification of partnering opportunities, competitor landscape analysis, market opportunity assessment and asset valuation. Sandya holds an M.Sc. in Biochemistry from the University of Geneva and a B.Sc. in Biochemistry from St Andrews University.

Before joining LifeSci Advisors, Steven Halper was a sell side research analyst for more than 27 years. During that time, Mr. Halper focused on Healthcare IT/Digital Health, Managed Care and Pharmaceutical Services industries at several major firms including Cantor Fitzgerald, FBR Capital Markets, Thomas Weisel Partners (TWP) and Donaldson, Lufkin & Jenrette (DLJ). During his analyst career. Mr. Halper was recognized by different organizations, including Institutional Investor, The Wall Street Journal, Starmine and TipRanks as one of the most highly ranked analysts in his respective coverage areas. Mr. Halper holds a BS in Economics from Binghamton University and an MBA from Fordham University. Mr. Halper is very active in career development at both Binghamton and Fordham and regularly advises students from both schools who wish to pursue a career in equity research.

Tim McCarthy brings over 21 years of investment experience across all healthcare sectors and capitalization ranges, focusing on life science investments at Kingdon Capital Management, Millennium Partners, Healthco/SAC Capital and Credit Suisse Asset Management. His extensive buy-side track record, when combined with specialty pharmaceutical sell-side research at CSFB, cash equities trainiing at Lehman Brothers, and public accounting experience at Arthur Andersen LLP, provides a well-rounded perspective to the team. Tim earned a BS with Special Attainments in Commerce from Washington and Lee University and an MBA in Finance and International Business from the Leonard N. Stern School of Business at New York University. He is a CFA charter holder and completed all CPA qualifications.

Alex is an experienced medical communications and strategy professional with over 15 years of scientific expertise in areas including hematology, immunology, diabetes and drug discovery. Prior to joining LifeSci, she was Medical Strategy Director at AREA 23, a leading health advertising agency in New York, where she advised clients on brand strategy, positioning and promotional messaging. Before AREA 23 she was employed in the BioSeek Division of Eurofins where she developed and managed scientific content for marketing materials. Earlier in her career, she worked at Q&A Market Research where she designed and conducted primary market research for drugs and devices used to treat diabetes. Alex holds a PhD in Metabolic Biochemistry from University of California at Berkeley and completed a Post Doctoral Fellowship at UCSF Diabetes Research Center. She holds a Bachelor of Arts in Biology from Lewis and Clark College, Portland, OR.

Chris Howerton has 15 years’ experience working in the biotechnology sector, having served as a sell-side analyst, senior management at a public biotechnology firm and academic researcher. As a sell-side analyst at Jefferies he covered over 75 biotechnology and specialty pharma companies, including approximately 40 IPOs. At Assembly Biosciences, Chris founded and managed a discovery platform, leading a team of ~15 scientists and managed a multi-million dollar partnership with Allergan (now part of AbbVie). Prior to that, he was an academic scientist and lecturer at both the University of Pennsylvania and Stanford University. Chris holds a BS and MS in Animal Science, as well as a PhD in evolutionary biology, all from the University of California, Davis.

Christopher Chu brings over 20 years of experience providing comprehensive investor relations programming and corporate communications across broad sectors, including healthcare and biotechnology. He has led strategic, internal and crisis communications, and transaction advisory services for IPOs, M&A, and public financings. Examples of his diverse transaction work include the reverse merger and introduction of Cellular Biomedicine Group to the capital markets, the IPO of Markit, its investor relations program buildout and subsequent merger with IHS; and also, the Republic of Ghana’s $1B sovereign bond raise. Before joining LifeSci, he held senior agency roles with The Piacente Group, Grayling, and Taylor-Rafferty. Additionally, he has led client investor relations advisory services on behalf of the Depositary Receipts group at J.P. Morgan. He completed pre-med studies and earned a B.A. in English from Stony Brook University. He also holds a M.S. in Information Systems from Pace University.

Dory A. (Lombardo) Kurowski has over 15 years of experience conducting corporate and investor communications for life science companies. She has worked both in-house at biopharmaceutical companies and for various life science clients at agencies, and therefore brings. the perspective of both sides to investor communications. Prior to joining LifeSci Advisors, Dory served as Director of Corporate Affairs at Progenics Pharmaceuticals, Inc. and the head of Corporate Communications and Investor Relations at Emisphere Technologies, Inc. Dory also served on the communications steering committee with Wyeth before and after Progenics’ first product, RELISTOR® was approved. Prior to being in-house, Dory worked for Feinstein Kean Partners, Morgen-Walke and LaVoie Strategic Communications with a wide range of life science clients, helping them pre- and post-IPO to craft their value propositions to the investment community and gain media exposure. During this time, she also was part of Biotechnology Industry Organization’s investor steering committee and organized the first thought leader panels for the annual BIO CEO and Investor Conference. Dory began her career in the life sciences as a Director of Research for Ledbetter Davidson International, a retained executive recruitment firm that was instrumental in placing many leading pharmaceutical and biotech executives. Dory holds a B.A. in Psychology from Manhattanville College and completed elective graduate work at NYU Stern School of Business and Boston College Carroll School of Management.

Gaia Vasiliver-Shamis has over 14 years of experience spanning industry, start-up, academia and government. Her expertise covers a breadth of therapeutic areas including infectious diseases, immunology, neurology, and rare diseases, as well as drugs at different stages of development and commercialization. Prior to joining LifeSci Advisors in 2023, Gaia worked at healthcare communications agencies including Omnicom’s Health Science Communications, Wunderman Thompson Health and Evolution Health Group. In these roles she led the strategic development and execution of content, advisory boards, and KOL training / engagement for US and global markets. Gaia holds a PhD in Immunology from New York University School of Medicine, an MBA from Emory University with honors in marketing as well as an MSc in Biomedical Science (Cum Laude), and a BSc in Biotechnology Engineering from the Technion – Israel Institute of Technology.

Garth Russell has approximately 20 years of healthcare IR and corporate communications experience. He has successfully worked with biotechnology and life science companies to establish investor relations capabilities that dovetail with broader corporate communications programs, including public relations and social media. Garth has provided strategic IR counsel to companies through IPOs, secondary offerings, M&A transactions and changes in management. Garth previously worked with KCSA Strategic Communications as Managing Director of Investor Relations, during which his responsibilities included overseeing the firm’s healthcare practice. He holds a B.S. in Marketing from SUNY Plattsburgh. Garth is a NIRI-National and NIRI-New York chapter member.

Glenn Garmont brings to LifeSci more than two decades of experience, not only in financial communications, but also as a sell-side equity research analyst. Prior to LifeSci, Glenn served as Senior Vice President at Rx Communications LLC, and, before that, Argot Partners, where he developed and executed strategic IR programs for an array of public and private companies across all development stages, in the biotechnology, specialty pharmaceuticals and medical device sectors. He also served as a Vice President on the health care team at ICR.

Before transitioning to investor relations, Glenn spent 12 years as a sell-side equity research analyst, first as a senior associate on multiple highly ranked research teams at Salomon Smith Barney, and then as a senior publishing analyst at boutique banking firms First Albany and ThinkEquity. As a senior analyst, Glenn built his expertise with research focused on health care services, including health care information technology, pharmacy benefit managers, pharmaceutical contract research and sales organizations, disease management, pharmacy automation, drug distribution and managed care.

Glenn earned a B.S. in Finance from Rutgers University and an MBA in Finance from the Stern School of Business at New York University.

Jess Lafferty, the Creative Director at LifeSci Advisors leads our in-house design team and is responsible for designing impactful and effective presentations for our clients. Jess’s background is rooted in transforming ideas and scientific data into impactful, professional, and visually appealing presentations. She has more than 20 years of experience in the creative marketing industry. Prior to joining LifeSci, Jess worked as the Director of Client Services for TheBlaze.com, where she conceptualized and designed strategic marketing campaigns for 200+ clients. Jess started her creative marketing career at Clear Channel Communications where she helped develop custom proposals and presentations for some of the world’s most recognized brands. Jess holds a Bachelor of Science in Healthcare Management from Towson University.

John P. Fraunces, Jr., has over 20 years of investment experience within the health care sector. John is founder of Synaptic Capital Group LLC, where he managed the equity long-short healthcare fund, Synaptic Medical Fund, L.P. He was also the Fund Manager of the Turner Medical Sciences Long-Short Mutual Fund, which was awarded Lipper’s equity long-short mutual fund of the year in 2015. Prior to Turner Investments, John served as the Portfolio Manager for the Health Care Sector with Solaris Asset Management, where he was responsible for stock selection across all of the firm’s equity strategies. He began his buyside career as a Senior Analyst with Gardner Lewis Asset Management, where he covered health care equities across the firm’s long-only and long-short portfolios. Before moving to the buy-side, John worked in the equity research departments of PaineWebber and Vector Securities. Supplementing life sciences investment experience is significant work in competitive intelligence. In addition to his investment experience, John has several years of experience conducting major competitive intelligence projects for global pharmaceutical and biotechnology companies in the fields of oncology, hematology, biosimilars, metabolic syndrome, obesity, diabetes, renal disease and neurological disorders. John began his career as an assistant scientist of peptide chemistry with Magainin Pharmaceuticals, where he conducted small molecule and peptide mimetic drug research for therapeutic applications in oncology and infectious disease. He holds a B.S. in Chemistry from the University of Scranton and received a M.B.A. from Lehigh University.

Joost is an expert in content visualization. He has over 20 years of experience in different areas of fundamental research and product development along with a PhD in Biomedical Science. Previously, Joost worked at Genmab for 12 years, where he specialized in content visualization, scientific communication, and early marketing strategies. Joost is based In Amsterdam, The Netherlands.

Joyce A. Lonergan has over 30 years of experience in the biopharmaceutical industry from her roles as a Sell Side Analyst, Corporate Communications/Investor Relations and Corporate Development Executive, Venture Investor, Company Co-Founder and Consultant with groups including Cowen & Company, Chiron, SR One/GSK, Mellitus LLC, Caxton Healthcare Ventures and Pine Cone Consulting Company, LLC and products in therapeutics, vaccines and diagnostics.

Joyce also held investment and business development roles at Vector Fund Management and Repligen Corporation. Ms. Lonergan started her career in research at Tufts Medical Center.

She graduated from Emmanuel College with a B.S. in biology, has an MBA from the Simmons College Graduate School of Management and is an alumna of the Springboard Healthcare Innovation Hub. Joyce is also a member of the Institutional Review Board for the New England Baptist Hospital.

Kristy Grabowski has over 18 years’ experience in the pharmaceutical industry and agency-affiliated medical communications, with emphasis on immunology and oncology. She has expertise in content development within medical affairs and publications arenas, including advisory boards, training module development, scientific communication platforms, facilitating and moderating web-based physician-working groups, abstract submissions, poster and oral presentations, primary and secondary manuscripts, and review articles. Prior to joining LifeSci, Kristy was VP, Scientific Strategy at Envision Communications. Before that she was a Scientific Team Lead at PAREXEL International. She also held medical communications and medical affairs roles at Hospira (a Pfizer company) and Baxter Healthcare. Earlier in her career, she was a Senior Medical Writer at Abbott. Kristy has a PhD in Cell Biology, Neurobiology, and Anatomy (with an emphasis on immunology and mucosal immunity) from Loyola University Medical Center, a BS in Cellular and Molecular Biology from Northern Illinois University and an AS in Biological Health Sciences from College of Lake County.

Lauren Marek is a creative and thoughtful science communication professional with broad expertise that includes microbiology, immunology, and cancer pharmacology. Prior to joining LifeSci Advisors, Lauren was a Senior Account Manager at AlphaBioCom, a medical communications agency in Pennsylvania, where she oversaw communications accounts spanning multiple therapeutic areas including oncology, neurology, and hemophilia. Prior to that, she was a Scientific Strategy Consultant at the University of Pennsylvania Center for Cytokine Storm Treatment and Laboratory, and a Post-Doctoral Research Scholar at Memorial Sloan Kettering Cancer Center. Lauren received a PhD in biomedical sciences (pharmacology) from Weill Cornell Graduate School of Medical Sciences, a Master of Science (microbiology and immunology) and a Bachelor of Science (microbiology, cum laude, with a minor in music) from the University of Rochester.

Lindsey Trickett joined LifeSci Advisors in 2024, bringing 20 years of biopharma industry experience spanning investor relations, corporate communications, finance, operations and marketing. She previously held senior in-house investor Relations and communications roles at Prelude Therapeutics (a small molecule precision oncology company), F-Star Therapeutics (bispecific oncology), and Intellia Therapeutics (CRISPR/Cas9 genome editing). Lindsey was employed for 12 years at Astra Zeneca, in a series of positions including Director, Investor Relations as well as Global Product & Portfolio Strategy. In the IR capacity, she acted as Astra Zenaca’s representative to actively manage the North American investor base. She frequently spoke on behalf of company at conferences and roadshows to communicate strategy, finances and progression of pipeline. Earlier in her career Lindsey held financial roles at US Airways and Bank of New York. She holds an undergraduate degree from the University of Kentucky, an MBA from Georgetown University, and is an active NIRI member.

Michael Wood has 20 years experience advising the biotechnology and life science industries, having worked as a sell side analyst, institutional investor and investor relations professional. As a sell-side analyst he worked at Lehman Brothers, UBS and Hambrecht & Quist (now part of JP Morgan). On the buy side, he spent four years working on a healthcare sector fund at Welch Capital Partners in New York. He has also acted as an independent advisor to venture capital firms on PIPE transactions and late stage private investments. Michael is a native of Dublin Ireland and holds an Honors Degree in Microbiology from Trinity College Dublin. He also studied Investor Relations and Corporate Communications at New York University.

Paul Arndt is an investor relations and corporate communications executive with nearly 30 years of corporate and agency experience. Previously, Paul was Sr. Manager of Investor Relations for Spectrum Pharmaceuticals during which time the company saw a more than 23-fold growth in its market capitalization, an increase in sell-side analyst coverage from two to seven and an increase in institutional ownership from 25% to more than 70% through proactive investor targeting. Prior to Spectrum, he led investor relations and corporate communications for NeoPharm, Inc., where he was responsible for executing long-term investor, corporate, employee, and media relations programs designed to develop and refine core messages to optimize value creation, contributing to a more than 500% increase in market capitalization and a doubling of analyst coverage through several corporate events. Paul also served as an IR consultant at Hill & Knowlton and David A. Noyes & Company. Paul earned his MBA from the Lake Forest Graduate School of Management in Chicago and his Bachelor of Arts in Communications from Quincy University in Quincy, Illinois. He is also a NIRI-National and NIRI-Chicago chapter member, and a former Officer of the NIRI-Orange County, California chapter.

Roxana has extensive communications and academic research experience in diverse areas including nanomaterials, peptides, nanofabricated healthcare devices, wound healing, and drug delivery. Roxana built up her industry experience while getting her Ph.D. She worked with startups through a collaboration between the CUNY ASRC and Futureworks NYC, and at tech accelerator VentureOut. Most recently, she worked with the life science investing group Mid-Atlantic Bio Angels. Roxana earned her Ph.D. at the Advanced Science Research Center at the Graduate Center, CUNY (City University of New York) in Chemistry specializing in nanotechnology and materials science. Prior to joining the Ph.D. program, Roxana worked at Cresilon, a medical device company that focuses on hemostatic technologies. Roxana is also Vice-President of Nanotech NYC a non-profit organization that aims at fostering the advancement of the nanotechnology and nanoscience communities in the greater New York City area.

Tom Johnson is seasoned professional with 20 years of experience managing internal and
external corporate communications for healthcare companies. He specializes in simplifying
complex business issues into a simple, consistent narrative that resonates with key audiences.
Prior to LifeSci, Tom managed investor relations for biotech and specialty pharmaceutical
companies in oncology (Delcath Systems, developer of a novel liver cancer therapy), GI imaging
(E-Z-EM, a leader in imaging contrasts), and cardiology (Vasomedical, developer of innovative
physical therapies for congestive heart failure.) Tom also spent several years as a producer for
a healthcare specialty agency now part of Havas Health. Tom holds a B.A. in history and political
science from Syracuse University.

Vicki Campbell, the Creative Director of LifeSci Advisors brings over 20 years of biomedical graphics experience to the team. She has extensive experience designing high impact slide decks, mechanism of action illustrations, PowerPoint templates, and figures for scientific publications. Prior to joining LifeSci, Vicki was the Digital Media Expert at The NemetzGroup, a dedicated team of consultants focused on life sciences that collaborate with cross-functional teams and provide counsel at all phases of the product lifecycle. She concurrently ran Vavoom! Design where she was responsible for dozens of IPO and private placement funding roadshows and held embedded roles with the teams at LocustWalk and MacDougall BioMedical Communications. Before she founded Vavoom! Design, Vicki worked as the Media Manager at Applied Molecular Evolution (now Eli Lilly) and was a Biomedical Graphics Artist at The Scripps Research Institute where she was formally trained to prepare biomedical graphics. Vicki has a degree from UCSD and 4 professional certificates from UCSD Extension.

Alexandra Schuman is an Associate Relationship Manager at LifeSci Partners. Prior to joining LifeSci, she worked at New York University while earning a Master’s degree in Psychology. She also holds a Bachelor of Arts in Psychology from University of California, San Diego where she graduated Summa Cum Laude. Alexandra has significant research experience from her participation in research labs during her academic tenure.

Brian Mullen an Associate Relationship Manager in LifeSci’s Advisors, LLC. Prior to joining the firm, he was Equity Research Associate on the Biotechnology team at J.P. Morgan covering. He received his Bachelor of Arts in Biochemistry, Molecular and Cellular Biology from Connecticut College.

Dean Schwartz is an Associate at LifeSci Advisors in New York. He holds a BA in Economics and minor in Business Administration from the University of North Carolina, Chapel Hill.

Ilana Koppel is an Associate Relationship Manager at LifeSci Advisors. She joined the firm in February 2024. Prior to this she was a researcher at a molecular biology lab at the University of Texas at Austin, where she received a Bachelor’s of Science in Biology and Marine Sciences. She is interested in the science communications and health care fields.

Kate Babcock is an Associate Relationship Manager at LifeSci Advisors, LLC. Prior to joining LifeSci Advisors in January 2022, she interned at Aruvant, a biotech company developing gene therapies for rare diseases, as a Communications Analyst. Kate earned a Bachelor of Science from Wesleyan University, where she triple-majored in Neuroscience and Behavior, Biology, and Science in Society.

Katherine Barry is an Associate Relationship Manager at LifeSci Advisors, LLC. Prior to joining LifeSci Advisors, she worked as a Market Access Consultant, specializing in supplemental payment pathways for medical devices, diagnostics, and specialty pharmaceuticals, in the US and Europe. Katherine earned her Bachelor of Arts in Economics from Loyola University Maryland.

Prior to joining LifeSci, Megan worked as an associate consultant for a boutique consultancy focused on innovation and growth strategy with clients primarily in the Technology, Healthcare, Financial Services and Consumer Packaged Goods industries. During her time there, she completed two Adtech projects for a major social media platform. Her responsibilities ranged from project coordination to data analysis and slide deck execution. Megan graduated from Brown University, where she earned a Bachelor of Arts in Biology and Master of Science in Biotechnology during which she completed a Master’s Thesis titled Human Cell-Based In Vitro Toxicity Testing Landscape: Market Analysis and Trends Report. She is also an alumni of the Brown Varsity Women’s Soccer team.

Nick Kerrigan is an Associate Relationship Manager with LifeSci Advisors, LLC. Previously, Nick has spent roughly 10 years working in consumer banking and wealth management at multiple major U.S. firms such as Citi, Bank of America and JPMorgan Chase. His primary focus was advising HNW families and small to middle market businesses in regards to banking operations, wealth and estate planning, investment portfolio management and lending. Nick received a Bachelor of Science degree in Business Administration with an emphasis in Finance, as well as a minor in Economics from Marist College

Raphael Wiesen is an Associate Relationship Managers with LifeSci Advisors, LLC. Before joining LifeSci, Raphael was a research associate at Fortress Biotech, focusing on asset evaluation and corporate development. He has a master’s degree in Biotech Management and Entrepreneurship as well as a BS in Psychology and Business. While doing his masters, Raphael was a fellow for the Mount Sinai Innovation Team handling company evaluations and strategy.

Sam Matel is an Associate Relationship Manager at LifeSci Advisors, LLC. Prior to joining LifeSci Advisors in July 2021, he interned at LifeSci Advisors and Appcast.io, a programmatic job advertisement company based out of Lebanon, NH. Sam earned a Bachelor of Science in Mathematics from St. Lawrence University

Summerlee Allen is an Associate Relationship Manager at LifeSci Advisors. She originally joined the firm as an Investor Relations Intern in 2016 and was quickly promoted. In 2020, she spent two years working as a Project Manager in Puerto Rico, where she helped companies establish offices in compliance with local governance and Act 20 & 22 tax laws. She rejoined the firm as an Associate Relationship Manager in 2022 and is interested in pursuing a career in Neurobiology. Summerlee graduated Cum Laude from New York University with a Bachelor of Arts in Economics and minors in Business and Mathematics.

Avi Levy is a business development associate at LifeSci Advisors. He received a Bachelor of Arts degree magna cum laude in political science from Binghamton University in 2024. He interned at the firm during the summer of 2023.

Carl Laroe is a Vice President in LifeSci’s New York office. Prior to joining LifeSci in 2019, Carl worked at IHS Markit in strategy and capital markets research roles. Carl holds his Bachelor of Arts in Economics with minors in Mathematics and Psychology from Wake Forest University.

Georgia leads business development strategy for LifeSci Advisors. Georgia has been working in the Life Sciences industry for nearly 10 years, beginning her career in corporate development, before moving into executive search where she partnered with biotech companies, primarily in the Boston area, to scale and refine their boards and executive teams through key inflection points. Georgia joined LifeSci advisors in March 2020.

Rob Windsor, J.D., serves as Chief Business Officer at LifeSci Partners. He has a deep and extensive background in the life science and financial services industries. Prior to joining LifeSci, Rob served as Head of Investor Relations at Seres Therapeutics, Inc. (Nasdaq: MCRB) as well as Sigilon Therapeutics (Nasdaq: SGTX), which was acquired by Eli Lilly. Rob was previously Managing Director at William O’Neil, an intricate SaaS software that blends fundamental, quantitative and technical equity analysis into mutual funds, hedge funds and registered investment advisers. Prior to that, Rob was Senior Vice President at Jefferies where he was instrumental in sourcing book-run investment banking deals and held similar roles at JP Morgan and UBS. Rob received his J.D. from New York Law School and B.A. from University of Colorado Boulder.

Aminah Sayid is an experienced Human Resources professional with a proven track record of delivering value-added solutions and driving human capital initiatives to support organizational goals. Currently serving as the Director of Human Resources at LifeSci Partners, Aminah brings a diverse skill set in HR operations, compliance, talent acquisition, and employee compensation and benefits.

Prior to her current role, Aminah worked as a Senior Manager of Human Resources at Sesen Bio, a global biopharmaceutical company. During her two-year tenure, she played a vital role in leading global HR operations and compliance, developing company policies, and advising the leadership team on all global HR matters. Her outstanding contributions included successfully completing a reverse merger transaction with Carisma Therapeutics, Inc., maximizing shareholder value and positioning the company for continued growth in the field of innovative immunotherapies for cancer treatment.

Prior to her role at Sesen Bio, Aminah served as a trusted advisor to business leaders on innovative talent acquisition strategies across prominent organizations such as Amneal Pharmaceuticals, MICRO, XPO Logistics, Northwell Health, Syneos Health Commercial Solutions, and Randstad USA.

With a Master of Labor and Employment Relations from Rutgers University, Aminah combines her academic background with her extensive experience in HR to drive organizational success.

Atonu brings experience from various industries with a focus on troubleshooting and operation. He brings a new perspective on operations and developing long term solutions in the Information Technology field. Prior to joining LifeSci, Atonu worked as a part of the IT Operations team for the New York City Department of Buildings, developing and engineering solutions.

Patrick serves as the General Counsel of LifeSci Partners and its affiliates. Prior to LifeSci, he was a legal and compliance consultant Oak Hill Advisors. Previously, Patrick was the General Counsel and Chief Compliance Officer of Brean Asset Management from 2019 to 2023 and a Legal & Compliance Manager at Centerbridge Partners from 2013 to 2018. Prior to Centerbridge, he served in various roles at Barclays, Citigroup and Goldman Sachs.

Patrick graduated from Fairfield University’s Dolan School of Business in 2001 with a B.S. in Information Systems and Operations Management and a minor in Finance. He received his J.D. from Fordham University School of Law in 2010.

Alyse has over 12 years of experience in corporate access, managing roadshows within the US. Prior to joining LifeSci Advisors, Alyse managed the North American Corporate Access desk at ABG Sundal Collier in New York. Prior to that, Alyse worked on the US Corporate Access and Conference team at Morgan Stanley. Alyse began her career at Goldman Sachs working on the US Syndicate Execution desk coordinating IPO roadshows for equity and debt capital markets.

Aida has over 20 years experience in corporate access, managing roadshows in the UK and Europe. Prior to joining LifeSci Advisors, Aida managed the North American equities corporate access team in London at RBC Capital Markets for 11 years. Prior to that, Aida worked with the US institutional equity sales team at Bear Stearns in London. Aida began her career working on the US equities desk at CIBC World Markets, London.

Alex Starr is a Non-Deal Roadshow Lead for the High Net Worth division. Joined LifeSci in 2019 with intentions to rapidly expand the High Net Worth roadshow offering for LifeSci Clients. Prior to joining LifeSci, Alex earned a degree from the Williams School of Commerce from Washington and Lee University.

Angela brings more than 15 years of experience in Corporate Access. She began her career in the Boston office of Credit Suisse working on the Institutional Equity Sales desk. Prior to joining LifeSci Advisors, Angela worked for SVB Leerink & Jefferies building relationships between senior corporate management teams and institutional investors with a focus in Healthcare. Angela graduated from University of Massachusetts with a Bachelor of Arts in Economics and a Minor in Business Management.

Anne has over 20 years’ experience in institutional equity sales. She started her career at Banque Harwanne and joined the Banque NSM (ABN AMRO Group) where she became head of Institutional Sales Europe. In 2004, she founded Finapsis an independent advisory firm specialising in fundraisings for listed and non listed companies, where she completed numerous transactions in healthcare and software. Anne graduated from Reims Management School.

Asia Rinkova is a Corporate Access and Investor relations Associate on LifeSci’s Israel team. Before joining LifeSci, she worked as a Relationship Manager at an early-stage investment fund MVST:MG, focusing on advanced technologies in the fields of blockchain, ad-tech and fintech. Previously, Asia worked as a Contract Associate at a healthcare intelligence and clinical research organization – PRA Health Science (acquired by ICON). Asia holds an MA in International Relations from Haifa University.

Brian Hicks joined LifeSci after 25+ years as sell side veteran of Wall Street. He has had several roles throughout his career encompassing Trading, Sales, Hedge Fund Partner, as well as Head of Sales. He has worked at boutique firms such as Soundview Technology Group and MKM Partners (where he ran sales and spearheaded their Equity research buildout) as well as Bulge Bracket and Mid Tier firms such as Bear Stearns, CIBC World Markets, and Raymond James. He has been involved in over 50 Life Sciences IPO’s and Follow ons in his career. He lives in Pound Ridge, NY with his wife and three sons.

Casey DeBaecke has more than 25 years of experience in Institutional Equity Sales. She began her career in the Boston Office of First Boston Corporation working in Equity Research. Casey then spent fifteen years at Credit Suisse where she was responsible for Institutional Equity Research Sales in the MidAtlantic Region. Prior to joining LifeSci Advisors, Casey worked for 10 years at UBS in the Institutional Equities Group providing Research Sales coverage to accounts in the MidAtlantic territory. Casey graduated from Boston College with a Bachelor of Science in Finance and a Minor in Asian Studies.

Christian Kirsebom has over 20 years of experience on Wall Street in corporate finance, institutional equity sales and private equity. Prior to joining LifeSci Advisors, he was an independent consultant working as interim CFO for start-up companies, assisting with investor relations and fund raising. Mr. Kirsebom held institutional equity sales roles at Jefferies & Company, Hambrecht & Quist (now part of JP Morgan) and Pacific Growth Equities, Inc. (merged with Wedbush Securities). Prior to his role in institutional sales, he was on the investment banking team at Pacific Growth Equities and Van Kasper & Company (acquired by Wells Fargo Securities), performing all corporate finance functions, including public offerings, merger & acquisitions, and private placements. Christian has a Candidatus Magisterii degree in Economic History and Political Science from the University of Oslo, Norway, and an MBA from the University of San Francisco. He was also a Sergeant in the Norwegian Navy.

Chris Nardo specializes in working with private companies, primarily offering strategic advice to venture stage companies and arranging non-deal roadshows with VCs and crossover investors. Prior to joining LifeSci Advisors, Chris led the non-deal roadshow team at The Ruth Group for five years where he focused on investor targeting and outreach for companies looking to meet with Venture Capitalists. Chris began his career at Angelo Gordon & Co. as a junior analyst. He graduated from Hofstra University with a BBA in Finance, Concentration in pre-med and a Minor in Chemistry.

Eric Ribner is a Managing Director and Relationship Manager of LifeSci’s Non-Deal Roadshow (NDR) business. He leads LifeSci’s efforts in introducing their clients to Family Offices, Financial Advisors, RIA’s and High Net Worth individuals. He also manages several client relationships at the firm. Eric spent more than 20 years working on Wall Street in various capacities, including as an Executive Director of Institutional Sales at Oppenheimer & Co. and on the buy-side, first as a Managing Director of Equity Research at NorthStar Capital Funds and then as a Senior Vice President at George Weiss Associates, where he helped manage over $200 million in equities in the financial, industrial, energy and metal sectors. Eric resides in Connecticut and has two children.

Over the past 20 years Floriane has developed close working relationships with a broad spectrum of European healthcare investors, including generalists, family offices, high net worth individuals and healthcare specialists. Floriane is based in Geneva, Switzerland.

Mr. Gaul has 25 years of experience in equity sales, including 14 years in institutional healthcare equity sales. Most recently, he was in equity research sales at Vertical Research Group, an independent equity research boutique, and previously served in similar roles at Adams, Harkness & Hill, Canaccord Adams, and Leerink Partners. During his career, Mr. Gaul has established and developed relationships with many top-tier buyside investors and sell-side analysts and investment bankers. Throughout his careeer, Mr. Gaul has managed numerous deal and non-deal roadshows in all major financial markets in the United States. He received a Bachelor of Arts degree in English and Economics from Wheaton College.

Joanne has over 20 years’ experience on the sellside having previously worked at CIBC World Markets and Oppenheimer within US and Canadian Institutional Equities and Capital Markets. Jo’s expertise is within corporate access, roadshow logistics, event and conference planning. Jo is based in London, UK.

Joe has 30+ years of Capital Markets experience. He started his professional career at Spear, Leeds & Kellogg, but spent most of his time (15 years) at Adams, Harnkess (now Canaccord Genuity). He ran Equity Trading and Corporate Services at Adams for about 8 years, and was a member of the Management Team, Deal Allocation Team and Compliance Committee. He was also a member of the Investment Committee and Trader for Winslow Asset Management (a subsidiary of Adams, now part of Brown Advisory). Joe has a BS in Economics from Bentley College, an MBA in Financial Management from Binghamton University, and resides with his family in Natick, MA.

Kylie has over 15 years’ experience on the sellside having previously worked at Canaccord Genuity in Australian Institutional Equities and Capital Markets. Kylie’s expertise is within corporate access, roadshow logistics, event and conference planning.

Mr. Caldwell has 20 years of experience in equity sales, primarily with emerging growth companies. Over half of this time was with Canaccord Genuity where he led the West Coast sales effort. Beginning his sell side career at Robertson Stephens, he also had similar roles at UBS, BB&T and Ladenburg. He has developed extensive relationships with buy side investors, sell side analysts and their equities desks, and corporate management teams. His expertise includes numerous equity transactions, including multiple IPOs, PIPEs, bought deals, cross border, and related follow-on offerings. A graduate of the U.S. Naval Academy, he began his career as a naval officer piloting ships in the Pacific Ocean.

Meirav brings over 17 years of Investor Relations experience, advising local, dual, and international listed Israeli public companies across industries, with expertise in Life Sciences and Bio-tech companies. Meirav has managed a first-time designated Family Office and HNW forum specializing in HNW activity and events. Working closely with the Israeli Capital market, Meirav has long-term relationships with Institutional investors, Strategic investors as well as Family Offices and HNW individuals. Meirav holds a Bachelor of Laws (LL.B) from Tel Aviv University and a Master of Business Administration (MBA) from Bar Ilan University

Michael Mills is an Associate for LifeSci’s Non-Deal Roadshow (NDR) Business. Prior to joining LifeSci in 2021, Michael worked at Maxim Group where he developed extensive sell side experience with both retail and institutional investors predominantly in the healthcare sector. In addition to business development and client management, he had the opportunity to work closely with Maxim’s Compliance department to ensure all capital markets activities aligned with SEC and FINRA regulations.

Prior to working at Maxim Group, Michael served as both a Financial Analyst and a Business Development Associate at Med-Metrix. Med-Metrix is a Revenue Cycle Management Firm that provided consulting to hospitals and large physicians practices.

Michael graduated Kean University with a Bachelor of Science in Finance and has earned FINRA issued Series 7 and 63 licenses.

Moran brings over 20 years of Investor Relations experience, having worked with Israel’s largest and most prominent private and publicly traded companies. Prior to joining LifeSci Advisors, Mrs. Meir-Beres was a senior account executive at KM Investor Relations, Israel’s first and largest IR firm, where she provided companies from a wide range of sectors ongoing investor and financial media relations consulting, as well as advisory services related to public and private securities offerings, mergers and acquisitions, and crisis management. Prior to joining KM, Ms Meir-Beres was part of the IR team at Teva (NYSE: TEVA), Israel’s largest healthcare company. Moran earned her BA and Master Degree in Law from Bar-Ilan University in Israel.

Niki has over 20 years’ experience in the industry starting out at Cowen in institutional equity sales and then at JP Morgan and Fortis Bank as healthcare specialist equity sales, marketing healthcare companies and deals to EU healthcare investors. In 2009 Niki founded Aetia Ltd, a FCA regulated firm focused on fundraisings for the healthcare sector, and has a track record raising capital for public and private life science companies at various stages of development.

Noa David joined LifeSci in March 2020 as an intern and in January 2021 transitioned to a Corporate Access Associate. Noa works on the Investor Relations and Corporate Access team as well as doing Business Development for LifeSci Israel. Noa holds a BA in Business Management and Entrepreneurship from Reichman University (formerly IDC) minoring in finance and is part of the honors program. She ran the IDC Venture Capital club program during her time at IDC.

Norma has over 20 years’ experience in institutional equity sales and has been heavily involved in marketing PIPEs, IPOs and secondary offerings to European specialist healthcare & tech funds. For the last 8 years Norma was healthcare specialist sales on the US institutional equity desk at Oppenheimer in London, covering UK, Swiss and German specialist investors. She spent the first half of her career on the US equity sales desk at CIBC in London where she had overall responsibility for Swiss investors and managed a team selling the firm’s US equity research product into Switzerland while personally focusing on healthcare and technology stocks. Norma earned a BSc in Financial Economics from University of London.

Ryan Gaitan graduated from Quinnipiac University with a B.Sc. in Finance and a Master of Business Administration with a Concentration in Finance. Prior to joining LifeSci Advisors, Ryan worked at The Ruth Group where he helped private companies seeking to raise capital by organizing non-deal roadshows with crossover investors and venture capital firms. Ryan began his career at Third Bridge Group as a research analyst.

Shiran brings over 8 years of experience in the financial industry. She is a certified Public Accountant by training and a certified Portfolio Manager. Prior her joining LifeSci Shiran was a Senior Investment Manager in Yelin Lapidot mutual funds, a highly valued investment house in Israel. Shiran’s experience including valuations and analysis of financial statements, participation in public offering, bonds issuances and private placements. Prior to joining Yelin Lapidot, Shiran was a Senior Associate at PricewaterhouseCoopers (PwC) were she audited international public and private companies from a wide range of fields ,partnerships and Venture Capital Funds . Shiran earned her BA in Accounting and Economics from the Hebrew University of Jerusalem and her MBA from Tel Aviv University.

Yael Riklin joined LifeSci in May 2021, prior to LifeSci, Yael was on the investor services team at Tzur Management (Acquired by Apex Group), a leading fund administrator in Israel. She previously worked in The Offices of the Prime Minister as a project manager. Yael has a BA in Economics and Business from Bar Ilan University.

Oengus has over 25 years’ experience in Finance and Administration. He started his career as an auditor with Ernst & Young and gained extensive international experience as CFO in several companies including Debiopharm. Oengus holds an accounting degree from University College Dublin, Ireland, and an MBA from INSEAD, France. He is fluent in three languages (English, French and German) and lives in Geneva, Switzerland.

Kiana Saghri, Manager of Business Development and Marketing, works with clients to strategize, market, and execute Bio-Pharma focused events. Kiana graduated from the University of St Andrews in 2022, with a bachelor’s degree in Neuroscience. Prior to joining LifeSci, she volunteered in the department of interventional cardiology at Mount Sinai Hospital and interned at Johnson & Johnson Pharmaceuticals.

Sara Parigian is co-founder and director at LifeSci Events, where she has established herself as a leading expert in organizing impactful events for companies within the life sciences industry. With an extensive background and wealth of industry knowledge, Sara works closely with clients, leveraging her expertise to develop and execute robust event strategies. Her primary focus is on delivering exceptional client service and driving business development initiatives. Since joining the LifeSci team in 2018, Sara has successfully orchestrated a wide range of corporate events, including influential key opinion leader gatherings, dynamic research and development days, engaging commercial events, and thought-provoking conferences. Through her meticulous attention to detail and dedication to excellence, Sara consistently ensures that each event is a resounding success, leaving a lasting impression on attendees. Sara received a Bachelor of Science degree in Finance and Marketing from University of South Carolina. This academic foundation, combined with her practical experience, equips her with a unique skill set to navigate the intersection of business and science effectively. With her unwavering commitment to delivering exceptional results and her ability to forge strong client relationships, Sara continues to drive LifeSci Events forward as a trusted partner for companies seeking impactful event solutions within the life sciences realm.

Wilson Hafner is the Manager of KOL Events and Strategy on the KOL Events Team, where she works with LifeSci’s clients and research team to plan, organize, and execute investor events. Prior to joining LifeSci, Wilson served as the Chief of Staff and Head of Marketing at a private equity-backed healthcare software startup, working alongside the CEO to manage strategic initiatives and scale operations. Wilson graduated from Dartmouth College in 2022 and holds a BA in both Psychology and Government (Modified with Economics and Philosophy).